Public health & disease

From disease eradication efforts to advances in vaccination and maternal health, this archive tracks real progress in public health. Stories here focus on what’s working — policies, interventions, and research that are improving and extending lives around the world.

DNA, for article on artificial DNA cancer

In a world first, Japenese scientists use artificial DNA to kill cancer cells

By / / Good News For Humankind

Artificial DNA that turns cancer’s own biology against itself marks a genuine conceptual leap in oncology. Japanese researchers at the University of Tokyo engineered synthetic molecules that lie dormant until they detect a chemical cancer cells overproduce — then restructure themselves into a signal the immune system reads as a threat, destroying the tumor from within. Early tests spanned multiple cancer types, suggesting broad potential. This kind of precision — working with the body’s existing defenses rather than overwhelming them — is exactly the direction cancer medicine has been reaching toward, and this research moves that goal meaningfully closer.

3M mask, for article on PFAS phase-out

3M to end ‘forever chemicals’ output at cost of up to $2.3 bn

By / / Good News For Humankind

3M, one of the world’s largest makers of PFAS, will halt all production of these “forever chemicals” by the end of 2025, walking away from a business that brought in roughly $1.3 billion a year. The company expects to absorb up to $2.3 billion in pre-tax charges to exit — a sign it sees long-term liability as the bigger risk than lost revenue. The move follows mounting pressure from regulators, lawsuits, and a coalition of fund managers overseeing $8 trillion in assets who urged dozens of companies to phase PFAS out. Compounds linked to cancer, thyroid disruption, and developmental harm have turned up in drinking water and food supplies worldwide, and 3M’s deadline signals that the era of treating them as ordinary industrial inputs is drawing to a close.

Brain model, for article on glioblastoma vaccine

Vaccine prolongs life of patients with aggressive brain cancer in new trial

By / / Good News For Humankind

Glioblastoma patients now have the most promising new treatment in nearly three decades, after a personalised vaccine more than doubled five-year survival rates in a large international trial. The vaccine works by extracting proteins from a patient’s own tumour and combining them with their white blood cells, training the immune system to recognise and destroy the cancer — with benefits seen even among those traditionally considered hardest to treat. If regulators approve it, this could signal a new era of personalised immunotherapy for cancers that have long resisted every available option.

Human eye up close, for article on Gennaris bionic vision system

Monash University develops world’s first bionic eye to fully restore vision in blind people

By / / Good News For Humankind

Gennaris, a bionic vision system from Monash University, could open a path to sight for people whose blindness stems from optic nerve damage — a group that most existing visual aids simply cannot help. The device bypasses the eye entirely, sending signals from a camera headset directly to tiles implanted in the brain, which then create perceivable points of light. Sheep trials confirmed the implants are safe and stable in brain tissue, and human trials are now being planned. If it succeeds, the underlying technology could eventually be adapted to assist people living with paralysis too.

Blood cells under microscope, for article on smart insulin, for article on lab-grown blood cells

First human patients receive transfusions of lab-grown blood cells

By / / Good News For Humankind

Lab-grown blood cells have reached a genuine turning point: manufactured red blood cells grown from stem cells have been safely transfused into human patients for the first time. What makes these cells special is their freshness — unlike donated blood, every lab-grown cell is the same age, meaning they should last closer to the full 120-day lifespan and reduce repeat transfusions. Early participants completed the process with no adverse effects. For millions worldwide living with blood disorders or rare blood types, this science crossing into human trials is the kind of progress that quietly changes everything.